Bausch Health/$BHC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bausch Health
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Ticker
$BHC
Sector
Primary listing
NYSE
Employees
20,700
Headquarters
Laval, Canada
Website
Bausch Health Metrics
BasicAdvanced
$2.2B
22.66
$0.27
0.43
-
Price and volume
Market cap
$2.2B
Beta
0.43
52-week high
$9.49
52-week low
$4.25
Average daily volume
1.6M
Financial strength
Current ratio
1.309
Quick ratio
0.791
Long term debt to equity
14,189.796
Total debt to equity
14,787.755
Interest coverage (TTM)
1.28%
Profitability
EBITDA (TTM)
3,116
Gross margin (TTM)
70.70%
Net profit margin (TTM)
0.99%
Operating margin (TTM)
19.22%
Effective tax rate (TTM)
82.92%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
4.36%
Return on equity (TTM)
-120.00%
Valuation
Price to earnings (TTM)
22.657
Price to revenue (TTM)
0.236
Price to book
-2.91
Price to tangible book (TTM)
-0.13
Price to free cash flow (TTM)
2.104
Free cash flow yield (TTM)
47.53%
Free cash flow per share (TTM)
2.857
Growth
Revenue change (TTM)
7.13%
Earnings per share change (TTM)
-119.52%
3-year revenue growth (CAGR)
6.37%
10-year revenue growth (CAGR)
0.72%
3-year earnings per share growth (CAGR)
28.26%
10-year earnings per share growth (CAGR)
-20.17%
What the Analysts think about Bausch Health
Analyst ratings (Buy, Hold, Sell) for Bausch Health stock.
Bulls say / Bears say
Bausch Health reported its ninth straight quarter of year-over-year growth in Q2 2025, with total revenue up 5% to $2.53 billion, adjusted EBITDA rising 6% to $842 million, and GAAP net income jumping to $148 million from $10 million a year ago (Nasdaq)
S&P Global Ratings raised Bausch Health’s issuer credit rating to B- from CCC+ in March 2025 after a $6.87 billion debt refinancing, removing short-term refinancing risk and strengthening the company’s credit outlook (Reuters)
The company’s diverse business performed well: the Salix segment grew organically by 12%, Solta Medical’s revenue climbed 26%, and the Bausch + Lomb unit delivered 3% constant-currency growth, showing broad-based segment strength (Nasdaq)
High leverage continues, with total debt at about $21.8 billion and the company considering a $5 billion debt issuance in early 2025 to refinance maturing obligations, indicating ongoing pressure to service debt (Bloomberg)
Bausch Health faces antitrust litigation risk, as a proposed class action lawsuit accuses the company and Teva of conspiring to delay the launch of generic Xifaxan, seeking damages and an injunction, with potential impacts on future cash flow and reputation (Reuters)
Revenue in the Diversified Products segment fell 13% year-over-year in Q2 2025, signaling price pressure in generics and neurology lines and underscoring notable weakness within the core portfolio (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Bausch Health Financial Performance
Revenues and expenses
Bausch Health Earnings Performance
Company profitability
Bausch Health News
AllArticlesVideos
Bausch Health Announces Results of Special Meeting of Shareholders
Accesswire1 week ago
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
Accesswire2 weeks ago
Bausch Health to Announce Third Quarter 2025 Results on October 29
Accesswire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bausch Health stock?
Bausch Health (BHC) has a market cap of $2.2B as of October 17, 2025.
What is the P/E ratio for Bausch Health stock?
The price to earnings (P/E) ratio for Bausch Health (BHC) stock is 22.66 as of October 17, 2025.
Does Bausch Health stock pay dividends?
No, Bausch Health (BHC) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next Bausch Health dividend payment date?
Bausch Health (BHC) stock does not pay dividends to its shareholders.
What is the beta indicator for Bausch Health?
Bausch Health (BHC) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.